KR20220004174A - GlyT1 억제제의 고체 형태 - Google Patents

GlyT1 억제제의 고체 형태 Download PDF

Info

Publication number
KR20220004174A
KR20220004174A KR1020217039503A KR20217039503A KR20220004174A KR 20220004174 A KR20220004174 A KR 20220004174A KR 1020217039503 A KR1020217039503 A KR 1020217039503A KR 20217039503 A KR20217039503 A KR 20217039503A KR 20220004174 A KR20220004174 A KR 20220004174A
Authority
KR
South Korea
Prior art keywords
ppm
compound
solid
solid form
magnetic resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217039503A
Other languages
English (en)
Korean (ko)
Inventor
조 쥐 가오
페터 지거
빙-스어우 양
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20220004174A publication Critical patent/KR20220004174A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217039503A 2019-05-01 2020-04-30 GlyT1 억제제의 고체 형태 Ceased KR20220004174A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
US62/841,401 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (1)

Publication Number Publication Date
KR20220004174A true KR20220004174A (ko) 2022-01-11

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217039503A Ceased KR20220004174A (ko) 2019-05-01 2020-04-30 GlyT1 억제제의 고체 형태

Country Status (25)

Country Link
US (2) US11447474B2 (https=)
EP (1) EP3962911A1 (https=)
JP (2) JP7513349B2 (https=)
KR (1) KR20220004174A (https=)
CN (1) CN113784966B (https=)
AR (1) AR118839A1 (https=)
AU (1) AU2020266566B2 (https=)
BR (1) BR112021020883A2 (https=)
CA (1) CA3138288A1 (https=)
CL (2) CL2021002837A1 (https=)
CO (1) CO2021014260A2 (https=)
CR (1) CR20210545A (https=)
DO (1) DOP2021000224A (https=)
EA (1) EA202192925A1 (https=)
EC (1) ECSP21082195A (https=)
IL (1) IL287630A (https=)
JO (1) JOP20210295A1 (https=)
MA (1) MA55801A (https=)
MX (1) MX2021013341A (https=)
PE (1) PE20212263A1 (https=)
PH (1) PH12021552741A1 (https=)
SG (1) SG11202111972YA (https=)
TW (1) TW202106680A (https=)
UA (1) UA129159C2 (https=)
WO (1) WO2020223419A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US9012489B2 (en) 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
IL270155B (en) * 2017-04-27 2022-07-01 Takeda Pharmaceuticals Co Heterocyclic compound
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) * 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Also Published As

Publication number Publication date
CN113784966B (zh) 2024-07-19
JOP20210295A1 (ar) 2023-01-30
JP2024100792A (ja) 2024-07-26
DOP2021000224A (https=) 2021-12-15
TW202106680A (zh) 2021-02-16
NZ781254A (en) 2025-03-28
CR20210545A (es) 2021-12-23
JP7714727B2 (ja) 2025-07-29
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
PH12021552741A1 (en) 2022-07-11
PE20212263A1 (es) 2021-11-29
CA3138288A1 (en) 2020-11-05
EA202192925A1 (ru) 2022-03-23
EP3962911A1 (en) 2022-03-09
ECSP21082195A (es) 2021-12-30
WO2020223419A1 (en) 2020-11-05
AU2020266566B2 (en) 2025-11-06
MX2021013341A (es) 2021-11-17
US11447474B2 (en) 2022-09-20
MA55801A (fr) 2022-03-09
US20220332710A1 (en) 2022-10-20
AR118839A1 (es) 2021-11-03
CL2024000829A1 (es) 2024-09-27
IL287630A (en) 2021-12-01
US20200347041A1 (en) 2020-11-05
SG11202111972YA (en) 2021-11-29
AU2020266566A1 (en) 2021-11-11
JP7513349B2 (ja) 2024-07-09
CO2021014260A2 (es) 2021-10-29
UA129159C2 (uk) 2025-01-29
BR112021020883A2 (pt) 2022-04-19
CN113784966A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7714727B2 (ja) ＧｌｙＴ１阻害剤の固体形態
CN105814067B (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
JP5315244B2 (ja) アザビシクロヘキサン誘導体の使用
WO2014128588A1 (en) Solid forms of a selective cdk4/6 inhibitor
WO2014137723A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
HUT77938A (hu) 7-Azabiciklo[2,2,1]-heptán- és -heptén-származékok és kolinerg receptor ligandumként történő alkalmazásuk
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3065077A1 (en) Novel biphenyl compound or salt thereof
TW202017924A (zh) 用於治療、改善或預防與tau聚集物相關之病症的新穎化合物
AU2006221699A1 (en) Crystal forms of an imidazole derivative
EP4565563A1 (en) 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
JP5139306B2 (ja) 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体
KR101800919B1 (ko) 크로먼 유도체들
JP7011596B2 (ja) ピペリジニルノシセプチン受容体化合物
CA2485537A1 (en) Novel compounds, their use and preparation
AP338A (en) A carbamoylchroman compound as selective 5-hydroxytryptamine.
EA045384B1 (ru) Твердые формы ингибитора glyt1
WO2006029549A1 (en) Quinuclidine compounds having quaternary ammonium group, it's preparation method and use as blocking agents of acetycholine
KR20200060404A (ko) 신규한 염
PT100431B (pt) Derivados do 5-(iminometano-10.11-di-hidro-5h-dibenzo{ a.d}ciclo-heptano que sao ligandos dos receptores de fenciclidina (pcp) e sua utilizacao
JPH08502293A (ja) 認識疾患の治療に有用な３，３−ジ置換された三環式および四環式インドリン−２−オン
JP2013144649A (ja) 新規ピラゾール誘導体
JPWO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000